by Evelyn Pringle
Part I
The pharmaceutical industry, with public health officials and the mainstream media acting as a mass marketing team, is about to pull off the biggest profiteering scheme in the history of the world. The swine flu hoax, perpetrated on a global level, will generate unheard of profits from a non-existent pandemic.
The Obama administration declared the spread of swine flu a public health emergency on April 26, 2009. The Associated Press reported that "Swine flu is now formally a pandemic, a declaration by U.N. health officials that will speed vaccine production and spur government spending to combat the first global flu epidemic in 41 years," on June 11, 2009.
"WHO chief Dr. Margaret Chan made the long-awaited declaration after the U.N. agency held an emergency meeting with flu experts and said she was moving to phase 6 -- the agency's highest alert level -- which means a pandemic is under way," the AP advised.
Since the "highest alert" warning was issued, the only estimation that has turned out to be true is that the drug companies are experiencing a windfall of tax dollars pouring into their coffers.
The US government "has committed $1.8 billion to companies to make a swine flu vaccine," Reuters reported on September 30, 2009, in an article with the headline, "Big pharma jumps back into flu business."
"Three big U.S. pharmaceutical companies announced vaccine deals this week," Reuters noted, for companies that included Johnson & Johnson, Abbott Laboratories and Merck.
"Abbott Labs bought a Belgian drug business, along with its flu vaccine facilities, for $6.6 billion. Johnson & Johnson invested $444 million in a Dutch biotech firm (Crucell) that makes and develops flu vaccines. Merck which already makes vaccines for shingles and other diseases, struck a deal to distribute flu shots made by Australian CSL," ABC News reported on October 14, 2009
"Smaller biotechs are also angling for a slice of the action, making vaccines one of the fastest-growing areas of research in the biotech industry," ABC noted.
Dr Robert Belshe, director of Saint Louis University's Center for Vaccine Development, told Reuters that the US is on the verge of recommending that all citizens get a flu shot. "We're at 270 million people who should get vaccinated. It's a big market. I think manufacturers are just now catching up," he said.
"The vaccine market is booming. It's an enormous growth area for pharmaceuticals at a time when other areas are not doing so well," Bruce Carlson, a spokesperson for the market research firm Kalorama, told ABC News.
On October 1, 2009, under the headline, "Vical shares soar on Navy's H1N1 contract," Fierce Vaccines advised that: "Anyone doubting just how hot H1N1 news is right now should check out Vical's stock price this morning."
"The developer announced a modest $1.3 million contract with the Navy to fund the manufacturing and testing of its swine flu vaccine and the company's stock shot up 22 percent," the report said.
On September 29, 2009, Reuters noted that the H1N1 flu pandemic is not "the first flu outbreak to have lifted the shares of small vaccine makers."
"The H5N1 bird flu scare that began in 2005 fueled a similar rise," the reports said. "And the media statements issued by companies then are similar to many of those issued today."
"In May 2006, Vical, for example, announced that its bird flu vaccine protected mice and ferrets against H5N1," Reuters recalled.
"This year, it said its H1N1 pandemic flu vaccine protected rabbits and mice. The news sent its shares soaring," the report noted.
The Obama administration declared the spread of swine flu a public health emergency on April 26, 2009. The Associated Press reported that "Swine flu is now formally a pandemic, a declaration by U.N. health officials that will speed vaccine production and spur government spending to combat the first global flu epidemic in 41 years," on June 11, 2009.
"WHO chief Dr. Margaret Chan made the long-awaited declaration after the U.N. agency held an emergency meeting with flu experts and said she was moving to phase 6 -- the agency's highest alert level -- which means a pandemic is under way," the AP advised.
Since the "highest alert" warning was issued, the only estimation that has turned out to be true is that the drug companies are experiencing a windfall of tax dollars pouring into their coffers.
The US government "has committed $1.8 billion to companies to make a swine flu vaccine," Reuters reported on September 30, 2009, in an article with the headline, "Big pharma jumps back into flu business."
"Three big U.S. pharmaceutical companies announced vaccine deals this week," Reuters noted, for companies that included Johnson & Johnson, Abbott Laboratories and Merck.
"Abbott Labs bought a Belgian drug business, along with its flu vaccine facilities, for $6.6 billion. Johnson & Johnson invested $444 million in a Dutch biotech firm (Crucell) that makes and develops flu vaccines. Merck which already makes vaccines for shingles and other diseases, struck a deal to distribute flu shots made by Australian CSL," ABC News reported on October 14, 2009
"Smaller biotechs are also angling for a slice of the action, making vaccines one of the fastest-growing areas of research in the biotech industry," ABC noted.
Dr Robert Belshe, director of Saint Louis University's Center for Vaccine Development, told Reuters that the US is on the verge of recommending that all citizens get a flu shot. "We're at 270 million people who should get vaccinated. It's a big market. I think manufacturers are just now catching up," he said.
"The vaccine market is booming. It's an enormous growth area for pharmaceuticals at a time when other areas are not doing so well," Bruce Carlson, a spokesperson for the market research firm Kalorama, told ABC News.
On October 1, 2009, under the headline, "Vical shares soar on Navy's H1N1 contract," Fierce Vaccines advised that: "Anyone doubting just how hot H1N1 news is right now should check out Vical's stock price this morning."
"The developer announced a modest $1.3 million contract with the Navy to fund the manufacturing and testing of its swine flu vaccine and the company's stock shot up 22 percent," the report said.
On September 29, 2009, Reuters noted that the H1N1 flu pandemic is not "the first flu outbreak to have lifted the shares of small vaccine makers."
"The H5N1 bird flu scare that began in 2005 fueled a similar rise," the reports said. "And the media statements issued by companies then are similar to many of those issued today."
"In May 2006, Vical, for example, announced that its bird flu vaccine protected mice and ferrets against H5N1," Reuters recalled.
"This year, it said its H1N1 pandemic flu vaccine protected rabbits and mice. The news sent its shares soaring," the report noted.
Vaccine Makers Fund Studies
On September 10, 2009, MedPage Today ran the headline: "H1N1 Vaccines Safe, Immunogenic in Single Dose".
"Two investigational vaccines against the pandemic H1N1 flu appear to be safe and to yield a robust immune response with a single dose," MedPage reported.
"Those findings," it said, "contained in two preliminary reports published online today in the New England Journal of Medicine -- are reassuring, experts said."
The first report is from an Australian study supported by CSL and the Department of Health and Aging of the Australian government. "All authors report being employees of CSL and several report having an equity interest in the company," according to MedPage.
The second report is from a British study supported by University Hospitals Leicester and Novartis. Study leader, Dr Iain Stephenson, "reported financial links with Novartis Vaccines, Sanofi Pasteur, Baxter Vaccines, Hoffmann–La Roche, and GlaxoSmithKline," MedPage noted.
"Two investigational vaccines against the pandemic H1N1 flu appear to be safe and to yield a robust immune response with a single dose," MedPage reported.
"Those findings," it said, "contained in two preliminary reports published online today in the New England Journal of Medicine -- are reassuring, experts said."
The first report is from an Australian study supported by CSL and the Department of Health and Aging of the Australian government. "All authors report being employees of CSL and several report having an equity interest in the company," according to MedPage.
The second report is from a British study supported by University Hospitals Leicester and Novartis. Study leader, Dr Iain Stephenson, "reported financial links with Novartis Vaccines, Sanofi Pasteur, Baxter Vaccines, Hoffmann–La Roche, and GlaxoSmithKline," MedPage noted.
Profits Galore
On September 21, 2009, Reuters reported that the United States had ordered 222 million doses of H1N1 vaccine from five drug makers that include GlaxoSmithKline, Sanofi-Pasteur, Australia's CSL, AstraZeneca's MedImmune division and Novartis.
CSL has contracts to supply $180 million worth of bulk antigen to the US. Sanofi-Pasteur is providing more than 100 million doses to the US, in a $690 million order.
On September 25, 2009, MedImmune said it has "received a federal order for 29 million more doses of its nasal H1N1 flu vaccine, bringing its total order to more than 40 million doses, with a value of about $453 million," according to Gazette.net.
Seeking Alpha reported on August 24, 2009, that the "Swiss company Novartis received an order for $346 million for antigen and $343.8 million for adjuvant totalling $690 million in July."
The most recent estimates have GlaxoSmithKline "reaping some $4.8 billion from the pandemic, between its Pandemrix vaccine, its Relenza antiviral drug, and other products such as antiviral face masks and flu diagnostics," Fierce Pharma reported on October 9, 2009.
On June 11, 2009, Kalorama Information issued a press release with the headline, "New Report Forecasts More Than Doubling of Vaccine Sales by 2013."
The new report titled, "Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry," forecasts the market "to more than double by 2013 due to a strong pipeline of new products and rising usage of current products around the world," Kalorama wrote.
In the press release, Kalorama described 2008 as another "stellar year for the world vaccine market," in which sales "grew 21.5% since 2007 to reach $19.2 billion."
"Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has," Kalorama noted.
CSL has contracts to supply $180 million worth of bulk antigen to the US. Sanofi-Pasteur is providing more than 100 million doses to the US, in a $690 million order.
On September 25, 2009, MedImmune said it has "received a federal order for 29 million more doses of its nasal H1N1 flu vaccine, bringing its total order to more than 40 million doses, with a value of about $453 million," according to Gazette.net.
Seeking Alpha reported on August 24, 2009, that the "Swiss company Novartis received an order for $346 million for antigen and $343.8 million for adjuvant totalling $690 million in July."
The most recent estimates have GlaxoSmithKline "reaping some $4.8 billion from the pandemic, between its Pandemrix vaccine, its Relenza antiviral drug, and other products such as antiviral face masks and flu diagnostics," Fierce Pharma reported on October 9, 2009.
On June 11, 2009, Kalorama Information issued a press release with the headline, "New Report Forecasts More Than Doubling of Vaccine Sales by 2013."
The new report titled, "Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry," forecasts the market "to more than double by 2013 due to a strong pipeline of new products and rising usage of current products around the world," Kalorama wrote.
In the press release, Kalorama described 2008 as another "stellar year for the world vaccine market," in which sales "grew 21.5% since 2007 to reach $19.2 billion."
"Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has," Kalorama noted.
Antiviral Drug Hype
On October 15, 2009, the Financial Times ran the headline: "Tamiflu boosts Roche sales figures," and reported that sales figures "were boosted by bumper demand for Tamiflu amid persistent fears about a global flu pandemic."
Tamiflu sales of $1.9 billion in the first nine months were more than four times ahead of the same period last year and third quarter sales figures were "nearly 10 times more than in the same period last year."
On July 22, 2009, Business Week reported that GlaxoSmithKline "expects to increase annual production of its inhalable anti-viral flu treatment Relenza threefold, to 190 million doses, by year end."
"Relenza sales for the three months ended June 30 were $99 million, up from just $5 million in the second quarter of 2008," the report noted.
The price of Tamiflu at a middle dose at DrugStore.com on August 26, 2009, was $93 for a packet of ten 75mg capsules. One inhaler of Relenza costs $64 at DrugStore.com.
Any good that will come from the swine flu propaganda campaign will accumulate solely with the profits of pharmaceutical industry.
Tamiflu sales of $1.9 billion in the first nine months were more than four times ahead of the same period last year and third quarter sales figures were "nearly 10 times more than in the same period last year."
On July 22, 2009, Business Week reported that GlaxoSmithKline "expects to increase annual production of its inhalable anti-viral flu treatment Relenza threefold, to 190 million doses, by year end."
"Relenza sales for the three months ended June 30 were $99 million, up from just $5 million in the second quarter of 2008," the report noted.
The price of Tamiflu at a middle dose at DrugStore.com on August 26, 2009, was $93 for a packet of ten 75mg capsules. One inhaler of Relenza costs $64 at DrugStore.com.
Any good that will come from the swine flu propaganda campaign will accumulate solely with the profits of pharmaceutical industry.
Part II
Back on May 9, 2009, Robin Robinson, a director at the Department of Health and Human Services who oversees pandemic responses, told the Washington Post that even as officials take steps to develop a swine flu vaccine with sufficient doses for every "man, woman and child," those plans would be dialed back if the pandemic "fizzles out."
The pandemic has fizzled out but the gravy train toward vaccine profits is still rolling. On September 16, 2009, Reuters reported that the death rate from the pandemic H1N1 swine flu was likely lower than earlier estimates.
"Barring any changes in the virus, I think we can say we are in a category 1 pandemic. This has not become clear until fairly recently," said Dr Marc Lipsitch of Harvard, an expert in infectious diseases, told a meeting of flu experts convened by the US Institute of Medicine.
"The news is certainly better than it was in May and even better than it was at the beginning of August," he noted.
The US government's Pandemic Severity Index has five categories, with a category 1 comparable to a seasonal flu epidemic. Seasonal flu has a death rate of less than 0.1 percent, Reuters reports. A category 5 would compare to the 1918 flu pandemic, which had an estimated death rate of 2% or more.
Lipsitch gathered information on how many people had reported influenza-like illness around the world, which may or may not actually be influenza; government reports of actual hospitalizations and confirmed deaths, and "came up with a range of mortality from swine flu from 0.007 percent to 0.045 percent," Reuters advises.
Having new information about how many people were infected and did not become severely ill or die makes the pandemic look very mild, Lipsitch said.
Minimal Swine Flu Deaths
The CIA World Factbook estimates the world population to be close to 6. 8 billion and the US population a little over 307 million. At the beginning of the swine flu propaganda campaign, it was predicted that the strength of the pandemic could be measured by watching statistics from the Southern Hemisphere, where flu season runs from May to September, the southern autumn and winter months.
The Southern Hemisphere holds between 10 and 12% of the world's population, meaning the Southern Hemisphere population would be roughly 760 million people, at 11% of the world's total.
According to population numbers for 2008 from Nation Master.com, and statistics from the FluCount.org website, the total number of swine flu deaths, as of September 30, 2009, was only 2,386, for thirteen countries in the Southern Hemisphere, and three countries that are mostly in the Southern Hemisphere, with a total population of 628.3 million people who would have received no vaccine against the swine flu.
India's population of approximately 1.17 billion people amounts to about one-sixth of the world's population, according to the World Factbook. As of October 11, 2009, India's swine flu death toll was a mere 385, according to the Times of India.
On October 6, 2009, the Associated Press reported that the "CDC doesn't have an exact count of swine flu deaths and hospitalizations, but existing reports suggest the infection has caused more than 600 deaths and more than 9,000 hospitalizations since the virus was first identified in April."
But yet the article further notes that "U.S. health authorities hope to give swine flu vaccinations to more than half the 300 million-plus population in just a few months."
The first swine death in the army, the largest military branch with 552,425 soldiers, did not occur until September 10, 2009, according to the Associated Press on October 1, 2009. It was reported to be the only death among the 1.4 million men and women in uniform at that time.
Yet all military personnel are required to receive the new swine flu vaccine. "The Pentagon has bought 2.7 million doses of vaccine, and 1.4 million of those will go to active-duty military personnel," the AP reported on September 29, 2009.
"National Guard troops on active duty are also required to receive the vaccine, as are civilian Defense Department employees who are in critical jobs," the article noted.
In 2007, people under 20 years of age made up 27.6% of the US population, according to the US Census Bureau, meaning roughly 82.8 million people were under 20. At the end of September, the CDC was reporting only 76 deaths from swine flu among children in the US.
Dr Anne Schuchat, director of the agency's National Center for Immunization and Respiratory Diseases, told reporters that the number of pediatric deaths ranged from 46 to 88 during the past three flu seasons, which is hard to reckon with the fact that the CDC is always claiming that 36,000 people die of the seasonal flu each year in the US.
But then experts say the CDC's 36,000 flu death statistic, echoed by the media each year, is greatly distorted. In a 2006 paper in the "Journal of American Physicians and Surgeons,} Dr David Ayoub and Dr F Edward Yazbak report that a review of the mortality data from the CDC's National Vital Statistics System (NVSS) reveals "these estimates are grossly exaggerated."
The NVSS reports preliminary mortality statistics and distinguishes between influenza-related deaths and pneumonia-related mortality, they explain.
"When the final report is issued, influenza mortalities are combined with the far more frequent pneumonia deaths, yielding an exaggerated representation of "influenza" deaths," they report.
"Pneumonia related mortality due to immunosuppression, AIDS, malnutrition, and a variety of other predisposing medical conditions is therefore combined with seasonal influenza deaths," the doctors point out.
"The actual influenza related deaths for the years 1997 to 2002 ranged from 257 to 1,765 annually," they advise.
"These values are further overestimated by combining deaths from laboratory-confirmed influenza infections with cases lacking laboratory confirmation," they say. "There were fewer than 100 annual cases of viral-confirmed deaths during this same period."
"Deaths occurring in women of reproductive ages were rare, approximately one per year," they note.
On the CDC's main flu page they state that about 36,000 people die from the flu in the US each year. But if you search a little harder, he says, you find the actual number of people who died from the flu in 2005 was 1,805, the most recent data available.
"In 2004, there were just 1,100 actual flu deaths," Dr Mercola reports on his website.
"The statistics the CDC gives are skewed partly because they classify those dying from pneumonia as dying from the flu, which is inaccurate," he says.
As of October 2, 2009, the World Health Organization was reporting only 4,108 swine flue deaths globally, five months into the pandemic, without any vaccines.
To put these numbers in perspective, consider that in 2005, more than 43,000 people died in motor vehicle accidents in the US, according to the Department of Transportation's National Highway Traffic Safety Administration.
The Southern Hemisphere holds between 10 and 12% of the world's population, meaning the Southern Hemisphere population would be roughly 760 million people, at 11% of the world's total.
According to population numbers for 2008 from Nation Master.com, and statistics from the FluCount.org website, the total number of swine flu deaths, as of September 30, 2009, was only 2,386, for thirteen countries in the Southern Hemisphere, and three countries that are mostly in the Southern Hemisphere, with a total population of 628.3 million people who would have received no vaccine against the swine flu.
India's population of approximately 1.17 billion people amounts to about one-sixth of the world's population, according to the World Factbook. As of October 11, 2009, India's swine flu death toll was a mere 385, according to the Times of India.
On October 6, 2009, the Associated Press reported that the "CDC doesn't have an exact count of swine flu deaths and hospitalizations, but existing reports suggest the infection has caused more than 600 deaths and more than 9,000 hospitalizations since the virus was first identified in April."
But yet the article further notes that "U.S. health authorities hope to give swine flu vaccinations to more than half the 300 million-plus population in just a few months."
The first swine death in the army, the largest military branch with 552,425 soldiers, did not occur until September 10, 2009, according to the Associated Press on October 1, 2009. It was reported to be the only death among the 1.4 million men and women in uniform at that time.
Yet all military personnel are required to receive the new swine flu vaccine. "The Pentagon has bought 2.7 million doses of vaccine, and 1.4 million of those will go to active-duty military personnel," the AP reported on September 29, 2009.
"National Guard troops on active duty are also required to receive the vaccine, as are civilian Defense Department employees who are in critical jobs," the article noted.
In 2007, people under 20 years of age made up 27.6% of the US population, according to the US Census Bureau, meaning roughly 82.8 million people were under 20. At the end of September, the CDC was reporting only 76 deaths from swine flu among children in the US.
Dr Anne Schuchat, director of the agency's National Center for Immunization and Respiratory Diseases, told reporters that the number of pediatric deaths ranged from 46 to 88 during the past three flu seasons, which is hard to reckon with the fact that the CDC is always claiming that 36,000 people die of the seasonal flu each year in the US.
But then experts say the CDC's 36,000 flu death statistic, echoed by the media each year, is greatly distorted. In a 2006 paper in the "Journal of American Physicians and Surgeons,} Dr David Ayoub and Dr F Edward Yazbak report that a review of the mortality data from the CDC's National Vital Statistics System (NVSS) reveals "these estimates are grossly exaggerated."
The NVSS reports preliminary mortality statistics and distinguishes between influenza-related deaths and pneumonia-related mortality, they explain.
"When the final report is issued, influenza mortalities are combined with the far more frequent pneumonia deaths, yielding an exaggerated representation of "influenza" deaths," they report.
"Pneumonia related mortality due to immunosuppression, AIDS, malnutrition, and a variety of other predisposing medical conditions is therefore combined with seasonal influenza deaths," the doctors point out.
"The actual influenza related deaths for the years 1997 to 2002 ranged from 257 to 1,765 annually," they advise.
"These values are further overestimated by combining deaths from laboratory-confirmed influenza infections with cases lacking laboratory confirmation," they say. "There were fewer than 100 annual cases of viral-confirmed deaths during this same period."
"Deaths occurring in women of reproductive ages were rare, approximately one per year," they note.
On the CDC's main flu page they state that about 36,000 people die from the flu in the US each year. But if you search a little harder, he says, you find the actual number of people who died from the flu in 2005 was 1,805, the most recent data available.
"In 2004, there were just 1,100 actual flu deaths," Dr Mercola reports on his website.
"The statistics the CDC gives are skewed partly because they classify those dying from pneumonia as dying from the flu, which is inaccurate," he says.
As of October 2, 2009, the World Health Organization was reporting only 4,108 swine flue deaths globally, five months into the pandemic, without any vaccines.
To put these numbers in perspective, consider that in 2005, more than 43,000 people died in motor vehicle accidents in the US, according to the Department of Transportation's National Highway Traffic Safety Administration.
Risks Outweigh Benefits
Studies also show flu vaccines do not work, and especially with children. On May 19, 2009, researchers at the International Conference of the American Thoracic Society in San Diego, presented a study that found children who received the trivalent inactivated influenza vaccine [TIV] had a three times greater risk of hospitalization for the flu than kids who were not vaccinated.
To determine whether the flu vaccine was effective in reducing the number of hospitalizations over consecutive flu seasons for 8 years, the researchers conducted a study of 263 children between the ages of 6 months and 18, evaluated at the Mayo Clinic between 1996 and 2006, with laboratory-confirmed influenza and reviewed records to determine which kids had received a flu shot before the illness and hospitalization.
According to the study, not only did the vaccine not prevent the flu, the children who received it got sicker than those who did not. Which means that for the 8 year period studied, health insurance companies, government programs and parents paid the cost of useless vaccines, doctors office calls and three times more flu-related hospitalizations, with the children suffering the harshest consequences.
On the "Healthy Skepticism" website, in a September 21, 2009 paper titled, "In the Face of Swine Flu, Common Sense and Science," Juan Gérvas, Honorary Professor, Public Health, School of Medicine, Autonomous University, in Madrid, Spain, reports that the "seasonal flu vaccine is relatively ineffective in children and adolescents, with a success rate of 33%, and is absolutely useless for children under 2 years."
"There are doubts about how effective it is in preventing flu in adults and the elderly," he added.
"We don't know anything about the effectiveness and safety of the swine flu vaccine which is ready to be marketed," Professor Gervas points out.
On April 29, 2008, Psychorg.com ran the headline, "Flu shot does not reduce risk of death," and reported that the "widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny," according to researchers in Alberta, Canada.
The study, published in the September, 2008, American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society, included more than 700 matched elderly subjects, half of whom had taken the vaccine and half of whom had not.
"After controlling for a wealth of variables that were largely not considered or simply not available in previous studies that reported the mortality benefit, the researchers concluded that any such benefit 'if present at all, was very small and statistically non-significant and may simply be a healthy-user artifact that they were unable to identify.'," the report said.
"Over the last two decades in the United Sates, even while vaccination rates among the elderly have increased from 15 to 65 percent, there has been no commensurate decrease in hospital admissions or all-cause mortality," said Dean Eurich, PhD, clinical epidemiologist and assistant professor at the School of Public Health at the University of Alberta.
"Further, only about 10 percent of winter-time deaths in the United States are attributable to influenza, thus to suggest that the vaccine can reduce 50 percent of deaths from all causes is implausible in our opinion," he advised.
On May 2, 2006, the National Post reported that, "Canada's first experiment in universal, free flu vaccine has cost Ontario taxpayers more than $200-million, but appears to have done nothing to cut the spread of influenza," a new study suggests.
"The Ontario initiative, the world's first universal flu campaign, distributes about five million vaccine doses a year at a current cost of $50- to $55-million, including promotion," the Post said, citing the Health Ministry.
The highly publicized offer of free flu shots to all 12 million Ontarians was launched in 2000 to try to ease pressure on emergency wards from flu patients, and cut the incidence and severity of the illness, the Post noted.
"Per-capita flu rates in the province have not fallen at all since the program was introduced in 2000, concluded the University of Ottawa research, published in the journal Vaccine," the Post reported.
"In fact," the Post said, "the average monthly incidence of the virus jumped over the first five years of the program, though researchers say it is too early to say that numbers are really on the rise."
"All we do know is rates haven't decreased, and there has been a lot of money spent," said Dianne Groll, the University of Ottawa professor who led the study. "The program was designed to reduce the incidence of flu, and this hasn't yet happened."
Dr Groll looked at the number of cases of laboratory-diagnosed flu reported to Health Canada between 1990 and 2005, and found that the rate between 1990 and 2000, when the program started, was 109 per 100,000 Ontarians. Since the launch of the campaign, "it jumped to 164." the Post said.
It's worth noting that the study also found the Ontario flu rates did not change relative to other provinces.
To determine whether the flu vaccine was effective in reducing the number of hospitalizations over consecutive flu seasons for 8 years, the researchers conducted a study of 263 children between the ages of 6 months and 18, evaluated at the Mayo Clinic between 1996 and 2006, with laboratory-confirmed influenza and reviewed records to determine which kids had received a flu shot before the illness and hospitalization.
According to the study, not only did the vaccine not prevent the flu, the children who received it got sicker than those who did not. Which means that for the 8 year period studied, health insurance companies, government programs and parents paid the cost of useless vaccines, doctors office calls and three times more flu-related hospitalizations, with the children suffering the harshest consequences.
On the "Healthy Skepticism" website, in a September 21, 2009 paper titled, "In the Face of Swine Flu, Common Sense and Science," Juan Gérvas, Honorary Professor, Public Health, School of Medicine, Autonomous University, in Madrid, Spain, reports that the "seasonal flu vaccine is relatively ineffective in children and adolescents, with a success rate of 33%, and is absolutely useless for children under 2 years."
"There are doubts about how effective it is in preventing flu in adults and the elderly," he added.
"We don't know anything about the effectiveness and safety of the swine flu vaccine which is ready to be marketed," Professor Gervas points out.
On April 29, 2008, Psychorg.com ran the headline, "Flu shot does not reduce risk of death," and reported that the "widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny," according to researchers in Alberta, Canada.
The study, published in the September, 2008, American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society, included more than 700 matched elderly subjects, half of whom had taken the vaccine and half of whom had not.
"After controlling for a wealth of variables that were largely not considered or simply not available in previous studies that reported the mortality benefit, the researchers concluded that any such benefit 'if present at all, was very small and statistically non-significant and may simply be a healthy-user artifact that they were unable to identify.'," the report said.
"Over the last two decades in the United Sates, even while vaccination rates among the elderly have increased from 15 to 65 percent, there has been no commensurate decrease in hospital admissions or all-cause mortality," said Dean Eurich, PhD, clinical epidemiologist and assistant professor at the School of Public Health at the University of Alberta.
"Further, only about 10 percent of winter-time deaths in the United States are attributable to influenza, thus to suggest that the vaccine can reduce 50 percent of deaths from all causes is implausible in our opinion," he advised.
On May 2, 2006, the National Post reported that, "Canada's first experiment in universal, free flu vaccine has cost Ontario taxpayers more than $200-million, but appears to have done nothing to cut the spread of influenza," a new study suggests.
"The Ontario initiative, the world's first universal flu campaign, distributes about five million vaccine doses a year at a current cost of $50- to $55-million, including promotion," the Post said, citing the Health Ministry.
The highly publicized offer of free flu shots to all 12 million Ontarians was launched in 2000 to try to ease pressure on emergency wards from flu patients, and cut the incidence and severity of the illness, the Post noted.
"Per-capita flu rates in the province have not fallen at all since the program was introduced in 2000, concluded the University of Ottawa research, published in the journal Vaccine," the Post reported.
"In fact," the Post said, "the average monthly incidence of the virus jumped over the first five years of the program, though researchers say it is too early to say that numbers are really on the rise."
"All we do know is rates haven't decreased, and there has been a lot of money spent," said Dianne Groll, the University of Ottawa professor who led the study. "The program was designed to reduce the incidence of flu, and this hasn't yet happened."
Dr Groll looked at the number of cases of laboratory-diagnosed flu reported to Health Canada between 1990 and 2005, and found that the rate between 1990 and 2000, when the program started, was 109 per 100,000 Ontarians. Since the launch of the campaign, "it jumped to 164." the Post said.
It's worth noting that the study also found the Ontario flu rates did not change relative to other provinces.
Part III
Public health officials now say they have quit keeping tabs on swine flu deaths because it is too difficult. A more likely explanation is that fear mongering would be impossible if they continued to announce the low rates of swine flu deaths and vaccine profits would take a nose dive.
"It's absurd to panic about swine flu, especially since it won't cause severe disease in many people," says Juan Gérvas, Honorary Professor, Public Health, School of Medicine, Autonomous University in Madrid, Spain, in the September 21, 2009 paper titled, "In the Face of Swine Flu, Common Sense and Science," on the Healthy Skepticism website.
"The current WHO messages, which are increasing fear of swine flu is a form of disease mongering," he warns.
"We need a health policy of common sense and self-control," Professor Gérvas advises.
"The present messages by Governments, the WHO and the media focusing on the worst case scenario and the detailed description of each death is the completely wrong approach," he says.
On July 21, 2009, Spiegel Online interviewed epidemiologist, Dr Tom Jefferson, who has worked for the Cochrane Collaboration, an international team of scientists, for 15 years.
"Sometimes you get the feeling that there is whole industry almost waiting for a pandemic to occur," Jefferson said.
He then listed the WHO, public health officials, virologists and the pharmaceutical companies. "They've built this machine around the impending pandemic," he said. "And there's a lot of money involved, and influence, and careers, and entire institutions!"
"And all it took was one of these influenza viruses to mutate to start the machine grinding," Jefferson pointed out.
"It's true that influenza viruses are unpredictable, so it does call for a certain degree of caution," he advised.
"But one of the extraordinary features of this influenza -- and the whole influenza saga," he said, "is that there are some people who make predictions year after year, and they get worse and worse."
"None of them so far have come about, and these people are still there making these predictions," he pointed out.
"For example," he asked, "what happened with the bird flu, which was supposed to kill us all?"
"Nothing," he said. "But that doesn't stop these people from always making their predictions."
Big Pharma Bonanza
On August 13, 2009, Dr Joseph Mercola, author of "The Great Bird Flu Hoax," explained how swine flu vaccine makers were set to profit by $50 billion.
"According to Margaret Chan, Director-General of the World Health Organization (WHO), vaccine makers could produce nearly FIVE BILLION pandemic flu shots per year in the best-case scenario," he wrote.
"And according to Business Week, wealthier countries like the U.S. and the U.K. will pay just under $10 per dose, while developing countries would pay less," he said. "If these facts hold true, Big Pharma stands to gain up to $49 billion a year on the swine flu vaccine alone."
As of 2009, "there has been no funding of a compensation program for children or adults injured or killed by vaccines or drugs used under an EUA (Emergency Use Authorization)," according to the National Vaccine Information Center.
In March 2008, Roche and Glaxo added new labels to Tamiflu and Relenza to warn of abnormal psychiatric behavior in some patients.
The drug makers said the revisions reflected recommendations made in November 2007 by an FDA advisory panel that reviewed the cases, which have been seen mostly in Japan.
"At that meeting, FDA staff described reports of about 700 cases of psychiatric adverse events for both drugs and 25 pediatric deaths from various causes in patients taking Tamiflu, reported to the agency through May 2007. No fatalities were reported for Relenza," the Guardian reported on March 4, 2008.
On August 10, 2009, the Financial Times reported that the "medicine now being widely handed out by the government for treating pandemic flu offers only modest benefit in children and adults in seasonal outbreaks of the virus," according to British researchers.
In an article in the British Medical Journal, a group led by Matthew Thompson at Oxford University said use in children under 13 of Tamiflu or Relenza reduced the duration of flu symptoms by an average of 12 to 36 hours with no decline in asthma or the need for antibiotics.
The authors concluded that the drugs "provide a small benefit by shortening the duration of illness in children with seasonal influenza and reducing household transmission".
"The findings came after a separate article published last week in Lancet Infectious Diseases, by researchers led by Jane Burch at the University of York, concluded that otherwise healthy adults showed a reduction in symptoms of just over half a day earlier when taking the drugs," the Gardian pointed out.
On August 20, 2009, The Indepedent reported that the Oxford researchers said children should not be given Tamiflu or Releza to combat swine flu.
They warned that Tamiflu could cause vomiting in some children, which could lead to dehydration and the need for hospital treatment.
Overall, "the researchers said, children who were otherwise healthy could suffer more harm than benefit from taking Tamiflu or another anti-viral, Relenza," the Independent advised.
Study co-author, Dr Carl Heneghan, a clinical lecturer at Oxford, said the current policy of giving Tamiflu for mild illness was an "inappropriate strategy".
Dr Heneghan said the only benefit found in the study was that children were back to normal half a day to one day earlier if taking Tamiflu or Relenza.
"The downside of the harms outweigh the one-day reduction in symptomatic benefits," he advised
"And he warned that widespread use of Tamiflu could result in the flu becoming resistant to the drug," the Independent reported.
Although the children in the studies analyzed were being treated for normal seasonal flu, Dr Thompson said the findings would extend to the current swine flu pandemic.
"I don't think we have got any reason to think our results would be any different," he told the Independent.
"The current swine flu is generally a mild flu illness...it does not seem that different from current seasonal flu," he said. "We would be happy to say our results apply to the current swine flu strain."
The research published in the BMJ "follows two recent studies which found that more than half of children taking Tamiflu suffered side-effects such as nausea, insomnia and nightmares," the Independent reported.
Tamiflu was banned by the Japanese ministry in 2007 for use with 10- to 19-year-olds.
"According to Margaret Chan, Director-General of the World Health Organization (WHO), vaccine makers could produce nearly FIVE BILLION pandemic flu shots per year in the best-case scenario," he wrote.
"And according to Business Week, wealthier countries like the U.S. and the U.K. will pay just under $10 per dose, while developing countries would pay less," he said. "If these facts hold true, Big Pharma stands to gain up to $49 billion a year on the swine flu vaccine alone."
As of 2009, "there has been no funding of a compensation program for children or adults injured or killed by vaccines or drugs used under an EUA (Emergency Use Authorization)," according to the National Vaccine Information Center.
In March 2008, Roche and Glaxo added new labels to Tamiflu and Relenza to warn of abnormal psychiatric behavior in some patients.
The drug makers said the revisions reflected recommendations made in November 2007 by an FDA advisory panel that reviewed the cases, which have been seen mostly in Japan.
"At that meeting, FDA staff described reports of about 700 cases of psychiatric adverse events for both drugs and 25 pediatric deaths from various causes in patients taking Tamiflu, reported to the agency through May 2007. No fatalities were reported for Relenza," the Guardian reported on March 4, 2008.
On August 10, 2009, the Financial Times reported that the "medicine now being widely handed out by the government for treating pandemic flu offers only modest benefit in children and adults in seasonal outbreaks of the virus," according to British researchers.
In an article in the British Medical Journal, a group led by Matthew Thompson at Oxford University said use in children under 13 of Tamiflu or Relenza reduced the duration of flu symptoms by an average of 12 to 36 hours with no decline in asthma or the need for antibiotics.
The authors concluded that the drugs "provide a small benefit by shortening the duration of illness in children with seasonal influenza and reducing household transmission".
"The findings came after a separate article published last week in Lancet Infectious Diseases, by researchers led by Jane Burch at the University of York, concluded that otherwise healthy adults showed a reduction in symptoms of just over half a day earlier when taking the drugs," the Gardian pointed out.
On August 20, 2009, The Indepedent reported that the Oxford researchers said children should not be given Tamiflu or Releza to combat swine flu.
They warned that Tamiflu could cause vomiting in some children, which could lead to dehydration and the need for hospital treatment.
Overall, "the researchers said, children who were otherwise healthy could suffer more harm than benefit from taking Tamiflu or another anti-viral, Relenza," the Independent advised.
Study co-author, Dr Carl Heneghan, a clinical lecturer at Oxford, said the current policy of giving Tamiflu for mild illness was an "inappropriate strategy".
Dr Heneghan said the only benefit found in the study was that children were back to normal half a day to one day earlier if taking Tamiflu or Relenza.
"The downside of the harms outweigh the one-day reduction in symptomatic benefits," he advised
"And he warned that widespread use of Tamiflu could result in the flu becoming resistant to the drug," the Independent reported.
Although the children in the studies analyzed were being treated for normal seasonal flu, Dr Thompson said the findings would extend to the current swine flu pandemic.
"I don't think we have got any reason to think our results would be any different," he told the Independent.
"The current swine flu is generally a mild flu illness...it does not seem that different from current seasonal flu," he said. "We would be happy to say our results apply to the current swine flu strain."
The research published in the BMJ "follows two recent studies which found that more than half of children taking Tamiflu suffered side-effects such as nausea, insomnia and nightmares," the Independent reported.
Tamiflu was banned by the Japanese ministry in 2007 for use with 10- to 19-year-olds.
1976 Swine Flu Replay
As a kick-off to the 1976 swine flu propaganda campaign, Salon Magazine reports that in February 1976, F David Mathews, Secretary of Health, Education, and Welfare told Americans:
"There is evidence there will be a major flu epidemic this coming fall. The indication is that we will see a return of the 1918 flu virus that is the most virulent form of the flu. In 1918 a half million Americans died. The projections are that this virus will kill one million Americans in 1976."
On March 24, 1976, President Gerald Ford asked Congress to appropriate $135 million "for the production of sufficient vaccine to inoculate every man, woman, and child in the United States."
"I am directing the Secretary of HEW David Mathews, and Assistant Secretary, Dr. Cooper, to develop plans that would make this vaccine available to all Americans during the 3-month period from September to November of this year," he said.
"I am asking each and every American to make certain he or she receives an inoculation this fall," Ford added.
"The reaction to the shot, I am told, may mean a few sore arms for a day or two--a very small price to pay for this vital protection," he advised.
The swine flu vaccination program began on October 1, 1976. Ten weeks later, after more than 40 million people were vaccinated, the government halted the program on December 16, 1976, due to the high number of severe adverse events occurring with the vaccine.
"The federal government ultimately reached court settlements and paid more than $90 million to hundreds of victims who said the 1976 vaccine caused neurological problems," according to a May 9, 2009 report in the Washington Post.
This time around, the Department of Health and Human Services "plans to eventually vaccinate at least 160 million people by December, with pregnant women, healthcare workers, children and young adults at the front of the line," Reuters reported on August 24, 2009.
"There is evidence there will be a major flu epidemic this coming fall. The indication is that we will see a return of the 1918 flu virus that is the most virulent form of the flu. In 1918 a half million Americans died. The projections are that this virus will kill one million Americans in 1976."
On March 24, 1976, President Gerald Ford asked Congress to appropriate $135 million "for the production of sufficient vaccine to inoculate every man, woman, and child in the United States."
"I am directing the Secretary of HEW David Mathews, and Assistant Secretary, Dr. Cooper, to develop plans that would make this vaccine available to all Americans during the 3-month period from September to November of this year," he said.
"I am asking each and every American to make certain he or she receives an inoculation this fall," Ford added.
"The reaction to the shot, I am told, may mean a few sore arms for a day or two--a very small price to pay for this vital protection," he advised.
The swine flu vaccination program began on October 1, 1976. Ten weeks later, after more than 40 million people were vaccinated, the government halted the program on December 16, 1976, due to the high number of severe adverse events occurring with the vaccine.
"The federal government ultimately reached court settlements and paid more than $90 million to hundreds of victims who said the 1976 vaccine caused neurological problems," according to a May 9, 2009 report in the Washington Post.
This time around, the Department of Health and Human Services "plans to eventually vaccinate at least 160 million people by December, with pregnant women, healthcare workers, children and young adults at the front of the line," Reuters reported on August 24, 2009.
Part IV
Those in control of the mainstream media have joined together with public health officials to provide the pharmaceutical industry with the best swine flu promotional campaign that money can buy.
In an October 7, 2009, OpEd News article titled, "The Centers for Disease Control: The Best Vaccination PR Firm Taxes Can Buy," the makers of the documentaries, "Vaccine Nation," and "Autism: Made in the USA," Richard Gale and Dr Gary Null wrote:
"If the flu season goes according to schedule, the vaccine industrial complex will be poised to join Wall Street for record year rip-off profits. We will also likely witness huge Pharma executive bonuses and perhaps gold-plated toilets.
"Even if the CDC statisticians' crystal ball used to forecast rampant swine flu infections turns into a complete bust -- which would only be one more added to many other failed flu predictions back to 1976 -- it will nevertheless be a very profitable failure as was the economic collapse for the banking cartel."
"In the US, such profits could never be accomplished without a dynamic, marketing initiative to convince Americans that vaccines will keep them protected and alive," they point out.
"And what better public relations machine for the vaccine complex, and all its supporters in health insurance and professional medical institutions, than our very own Centers for Disease Control and the Department of Health and Human Services?" they wrote.
The CDC is "formulating a $4.8 million multimedia campaign to encourage people to get vaccinated and help alleviate concerns and confusion, including radio and television public service announcements, print ads, and messages delivered via Twitter, RSS feeds and video podcasts on YouTube," according to the August 22, 2009 Washington Post.
Government health officials "are mobilizing to launch a massive swine flu vaccination campaign this fall that is unprecedented in its scope -- and in the potential for complications," the Post reported. "The campaign aims to vaccinate at least half the country's population within months."
The federal government "has spent close to $2 billion to buy up to 195 million doses of vaccine and adjuvant," according to the Post.
"The government is prepared to buy enough to vaccinate every person -- 600 million doses all together -- if the pandemic or demand warrants it," the report said. "That could increase the cost to $5 billion for the vaccine alone."
"It would cost at least $9 billion to administer the vaccine to the entire population, according to the Association of State and Territorial Health Officials," the Post advised.
There is nothing free about the flu vaccination campaigns in the US. Americans will end up footing the bill in one way or another, along with the medical care for persons injured by the vaccine.
"As always with pandemic flus, taxpayers are footing the $1.5 billion check for the 250 million swine flu vaccines that the government has ordered so far and will be distributing free to doctors, pharmacies and schools," ABC News pointed out on October 14, 2009.
"In addition," the report said, "Congress has set aside more than $10 billion this year to research flu viruses, monitor H1N1's progress and educate the public about prevention."
On October 5, 2009, the Associated Press advised that the H1N1 vaccine itself is free because the government bought it with your tax dollars. "But providers can charge a small fee for administering it, usually about $20. Regular flu shots tend to cost up to $35," the AP said.
Doctors are also set to profit greatly from administering the vaccines. The American Medical Association, which publishes Current Procedural Terminology (CPT), has even revised one CPT code and issued another for use in billing for H1N1 vaccines.
The changes "will streamline the reporting and reimbursement procedure for physicians and healthcare providers who are expected to administer nearly 200 million doses of the H1N1 vaccine in the U.S.," the AMA said in a statement.
Media as a PR Firm
"In too many ways, the mainstream media has become little more than a corporate mouthpiece, whoring itself out to the highest bidder / advertiser," warns Mike Adams, in the September 18, 2009, Natural News report titled, "Ten Swine Flu Lies Told by the Mainstream Media."
The "distorted reporting on the swine flu vaccine has been one of the greatest media frauds ever perpetrated," he says.
"The media has in every way contributed to the widespread ignorance of the American people on the subject of vitamin D and natural immune-boosting defenses that could reduce swine flu fatalities," Adams points out.
"Rather than informing readers," he says, "the MSM has made it a point to keep the people stupid, and in doing so, the media has failed its only mission and betrayed the very audience it claims to serve."
The "distorted reporting on the swine flu vaccine has been one of the greatest media frauds ever perpetrated," he says.
"The media has in every way contributed to the widespread ignorance of the American people on the subject of vitamin D and natural immune-boosting defenses that could reduce swine flu fatalities," Adams points out.
"Rather than informing readers," he says, "the MSM has made it a point to keep the people stupid, and in doing so, the media has failed its only mission and betrayed the very audience it claims to serve."
Vested Interest in Spreading Swine Flu Propaganda
The media moguls controlling the MSM world-wide have a vested interest in hyping the swine flu epidemic to boost sales of vaccines and funding for the vaccine research industry.
Rupert Murdoch is a major shareholder, chairman and managing director of News Corporation. News Corp was the world's second largest media conglomerate, behind Walt Disney Company, as of 2008, and the world's third largest in entertainment as of 2009, according to Wikipedia, the online encyclopedia.
In late 2003, Murdoch acquired a 34 percent stake in Hughes Electronics, the operator of Direct TV, the largest American satellite TV system. In 2004, Murdoch announced that he was moving News Corp's headquarters from Australia to the US.
According to the Columbia Journalism Review, News Corp owns Fox Broadcasting Company and 27 Fox Television Stations in major cities all over the country, in addition to many cable channels, including the Fox News channel, and 20th Century Fox film companies and studios. News Corp also owns the New York Post, the Wall Street Journal and Dow Jones.
On February 2, 2009, GlaxoSmithKline announced the appointment of James Murdoch, son of media mogul Rupert Murdoch, as a non-executive director. Murdoch joined the company on May 20, 2009 and will also be a member of Glaxo's Corporate Responsibility Committee.
Murdoch is Chairman and Chief Executive of News Corporation, Europe and Asia, and "has direct responsibility for the strategic and operational development of News Corporation's television, newspaper and related digital assets in Europe, Asia and the Middle East," Glaxo noted.
Murdoch is in charge of "News International, owner of four British newspapers -- the Times, Sunday Times, Sun and News of the World," according to an article titled, "The Invisible Mogul: Meeting James Murdoch," by Sophie Barker, in the spring 2009 issue of "Intelligent Life Magazine."
"His TV channels reach 200m people across 60-odd countries," Barker reports.
The Murdoch Children's Research Institute (MCRI) is the largest research Institute in Australia specialising in child and adolescent health. "Located on the campus of the Royal Children's Hospital, Melbourne, it is affiliated with the University of Melbourne," its website states.
Rupert Murdoch's mother, Dame Elisabeth Murdoch, is the widow of Australian newspaper publisher, Sir Keith Murdoch. She married Keith Murdoch, 23 years her senior, in 1928 and inherited the bulk of his fortune when he died in 1952. She was appointed a Dame Commander of the Order of the British Empire in 1963.
"It was through seed funding provided by Dame Elisabeth" in 1984, that the MCRI went on "to become the largest and most prestigious child health research centre in Australia," according to the February 7, 2009, Frankston Standard Leader.
Elisabeth is a life-governor of the Royal Women's Hospital and a Patron of the Murdoch Children's Research Institute, according to the Australian Women's Register.
In 2009, MCRI has "over 1100 researchers," the Leader reports. Rupert Murdoch's daughter-in-law, Sarah Murdoch, has been the ambassador for the MCRI and a member of the development board since 2000.
The MCRI has six research themes, including one for "Infection, immunity and environment," with research conducted at the "Centre for Clinical Research Excellence in Child and Adolescent Immunisation."
The CCRE is a joint MCRI, Melbourne University, and Menzies School of Health Research collaboration whose secretariat is located in the Department of General Medicine at the Royal Children's Hospital campus.
"Research focuses on clinical trials of new vaccines in healthy infants, children and adolescents, the epidemiology of vaccine preventable diseases (VPDs) and evaluation of the impact of population-delivered vaccine programs, and mathematical modelling of vaccine-preventable diseases," the MCRI website advises.
Under "Collaborations," the site lists: "Promotion of collaborations with Australian and overseas immunisation researchers, policy-makers, service providers and the vaccine industry."
Under a heading titled, "Commercialisation," the website states: "The Murdoch Children's Research Institute invites interested parties to take up the opportunity to invest in its wide portfolio of commercial biotechnologies."
In a July 27, 2009 press release, MCRI announced that children "are being recruited for a pandemic H1N1 swine flu vaccine trial set to begin in Melbourne next week."
"About 100 Victorian children aged between 6 months to eight years are needed for the study, which will be run by the Murdoch Childrens Research Institute and the University of Melbourne from as early as next week," the press release stated.
"They will be among 400 children recruited across five states for the Federal Government required trials of the vaccine, produced by Australian biopharmaceutical company CSL," it advised.
Four years ago, on October 4, 2005, the Murdoch Childrens Research Institute issued a similar press release stating: "Bird flu vaccine trial to begin."
"TRIALS of a bird flu vaccine are set to begin in Melbourne this week as researchers prepare against the threat of an influenza pandemic," MCRI advised.
"The study, a collaborative project between the Murdoch Childrens Research Institute and University of Melbourne, is being sponsored by Australian pharmaceutical company CSL Limited," the press release stated.
Media mogul, Mortimer Zuckerman, also has a research center named after him. On May 10, 2009, the New York Times reported that Zuckerman had "pledged $100 million to Memorial Sloan-Kettering Cancer Center, the largest donation in the hospital's history and one of the largest ever given to an American medical center."
"Sloan-Kettering will name its new research center on the Upper East Side for Mr. Zuckerman, the real estate developer and owner of The Daily News and U.S. News & World Report," the Times noted.
"Zuckerman advances vaccine research and development at the Mortimer B. Zuckerman Research Center in association with the Memorial Sloan-Kettering Cancer Center and Rockefeller University," according to Dr Leonard Horowitz, a Harvard-trained authority in vaccinations and emerging diseases with a masters degree in public health, in a September 30, 2009, report by Sherri Kane.
Zuckerman is also a leading financier of the American Lyme Disease Foundation that heavily promoted GlaxoSmithKline's disastrous Lymerix vaccine, Horowitz says.
"This vaccine was pulled from the market following hundreds-of-thousands of reported cases of recipients suffering post-vaccination symptoms of Lyme disease," he reports.
The great bird flu hoax serves as an excellent example of use of the MSM to pump out fear mongering propaganda. On June 20, 2005, Zuckerman wrote a commentary in US News and World Report titled, "A Nightmare Scenario – H5N1 Pandemic," and stated:
"Should it develop certain genetic changes, international health experts warn, bird flu could spark a global pandemic, infecting as much of a quarter of the world's population and killing as many as 180 million to 360 million people--at least seven times the number of AIDS deaths, all within a matter of weeks."
"In the worst previous catastrophic pandemic, in 1918, more than 20 million died from the Spanish flu," Zuckerman wrote.
"We must prioritize research money to develop a vaccine, expand the production of flu vaccine, and stockpile antiviral medications," he advised.
On December 8, 2005, Bloomberg ran an article with the headline, "Bird Flu Pandemic May Cost U.S. Economy $675 Billion," in which Senate Majority Leader Bill Frist was quoted as saying, "A pandemic of bird flu in humans may cost the U.S. economy $675 billion, including lost work time and disruptions in supply chains."
This time around, on October 14, 2009, ABC News reported that "the Trust for America's Health, a Washington-based non-profit organization, estimates that a severe pandemic could push down GDP by more than 5 percent and cost Americans $683 billion."
"We're not seeing a pandemic that's this severe," says Jeff Levi, director of the group. "We've dodged a lot of bullets."
Last but not least, Thomas H Glocer is the Chief Executive Officer of the Thomson Reuters Corporation. On November 26, 2007, Merck announced that Thomas Glocer, Chief Executive Officer, Reuters Group PLC, "will join the Company's Board of Directors effective Nov. 27."
"Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs," the press release stated.
As shown above, the mainstream media cannot be objective when reporting on the swine flu because it is riddled with conflicts of interest involving the vaccine industry.
Rupert Murdoch is a major shareholder, chairman and managing director of News Corporation. News Corp was the world's second largest media conglomerate, behind Walt Disney Company, as of 2008, and the world's third largest in entertainment as of 2009, according to Wikipedia, the online encyclopedia.
In late 2003, Murdoch acquired a 34 percent stake in Hughes Electronics, the operator of Direct TV, the largest American satellite TV system. In 2004, Murdoch announced that he was moving News Corp's headquarters from Australia to the US.
According to the Columbia Journalism Review, News Corp owns Fox Broadcasting Company and 27 Fox Television Stations in major cities all over the country, in addition to many cable channels, including the Fox News channel, and 20th Century Fox film companies and studios. News Corp also owns the New York Post, the Wall Street Journal and Dow Jones.
On February 2, 2009, GlaxoSmithKline announced the appointment of James Murdoch, son of media mogul Rupert Murdoch, as a non-executive director. Murdoch joined the company on May 20, 2009 and will also be a member of Glaxo's Corporate Responsibility Committee.
Murdoch is Chairman and Chief Executive of News Corporation, Europe and Asia, and "has direct responsibility for the strategic and operational development of News Corporation's television, newspaper and related digital assets in Europe, Asia and the Middle East," Glaxo noted.
Murdoch is in charge of "News International, owner of four British newspapers -- the Times, Sunday Times, Sun and News of the World," according to an article titled, "The Invisible Mogul: Meeting James Murdoch," by Sophie Barker, in the spring 2009 issue of "Intelligent Life Magazine."
"His TV channels reach 200m people across 60-odd countries," Barker reports.
The Murdoch Children's Research Institute (MCRI) is the largest research Institute in Australia specialising in child and adolescent health. "Located on the campus of the Royal Children's Hospital, Melbourne, it is affiliated with the University of Melbourne," its website states.
Rupert Murdoch's mother, Dame Elisabeth Murdoch, is the widow of Australian newspaper publisher, Sir Keith Murdoch. She married Keith Murdoch, 23 years her senior, in 1928 and inherited the bulk of his fortune when he died in 1952. She was appointed a Dame Commander of the Order of the British Empire in 1963.
"It was through seed funding provided by Dame Elisabeth" in 1984, that the MCRI went on "to become the largest and most prestigious child health research centre in Australia," according to the February 7, 2009, Frankston Standard Leader.
Elisabeth is a life-governor of the Royal Women's Hospital and a Patron of the Murdoch Children's Research Institute, according to the Australian Women's Register.
In 2009, MCRI has "over 1100 researchers," the Leader reports. Rupert Murdoch's daughter-in-law, Sarah Murdoch, has been the ambassador for the MCRI and a member of the development board since 2000.
The MCRI has six research themes, including one for "Infection, immunity and environment," with research conducted at the "Centre for Clinical Research Excellence in Child and Adolescent Immunisation."
The CCRE is a joint MCRI, Melbourne University, and Menzies School of Health Research collaboration whose secretariat is located in the Department of General Medicine at the Royal Children's Hospital campus.
"Research focuses on clinical trials of new vaccines in healthy infants, children and adolescents, the epidemiology of vaccine preventable diseases (VPDs) and evaluation of the impact of population-delivered vaccine programs, and mathematical modelling of vaccine-preventable diseases," the MCRI website advises.
Under "Collaborations," the site lists: "Promotion of collaborations with Australian and overseas immunisation researchers, policy-makers, service providers and the vaccine industry."
Under a heading titled, "Commercialisation," the website states: "The Murdoch Children's Research Institute invites interested parties to take up the opportunity to invest in its wide portfolio of commercial biotechnologies."
In a July 27, 2009 press release, MCRI announced that children "are being recruited for a pandemic H1N1 swine flu vaccine trial set to begin in Melbourne next week."
"About 100 Victorian children aged between 6 months to eight years are needed for the study, which will be run by the Murdoch Childrens Research Institute and the University of Melbourne from as early as next week," the press release stated.
"They will be among 400 children recruited across five states for the Federal Government required trials of the vaccine, produced by Australian biopharmaceutical company CSL," it advised.
Four years ago, on October 4, 2005, the Murdoch Childrens Research Institute issued a similar press release stating: "Bird flu vaccine trial to begin."
"TRIALS of a bird flu vaccine are set to begin in Melbourne this week as researchers prepare against the threat of an influenza pandemic," MCRI advised.
"The study, a collaborative project between the Murdoch Childrens Research Institute and University of Melbourne, is being sponsored by Australian pharmaceutical company CSL Limited," the press release stated.
Media mogul, Mortimer Zuckerman, also has a research center named after him. On May 10, 2009, the New York Times reported that Zuckerman had "pledged $100 million to Memorial Sloan-Kettering Cancer Center, the largest donation in the hospital's history and one of the largest ever given to an American medical center."
"Sloan-Kettering will name its new research center on the Upper East Side for Mr. Zuckerman, the real estate developer and owner of The Daily News and U.S. News & World Report," the Times noted.
"Zuckerman advances vaccine research and development at the Mortimer B. Zuckerman Research Center in association with the Memorial Sloan-Kettering Cancer Center and Rockefeller University," according to Dr Leonard Horowitz, a Harvard-trained authority in vaccinations and emerging diseases with a masters degree in public health, in a September 30, 2009, report by Sherri Kane.
Zuckerman is also a leading financier of the American Lyme Disease Foundation that heavily promoted GlaxoSmithKline's disastrous Lymerix vaccine, Horowitz says.
"This vaccine was pulled from the market following hundreds-of-thousands of reported cases of recipients suffering post-vaccination symptoms of Lyme disease," he reports.
The great bird flu hoax serves as an excellent example of use of the MSM to pump out fear mongering propaganda. On June 20, 2005, Zuckerman wrote a commentary in US News and World Report titled, "A Nightmare Scenario – H5N1 Pandemic," and stated:
"Should it develop certain genetic changes, international health experts warn, bird flu could spark a global pandemic, infecting as much of a quarter of the world's population and killing as many as 180 million to 360 million people--at least seven times the number of AIDS deaths, all within a matter of weeks."
"In the worst previous catastrophic pandemic, in 1918, more than 20 million died from the Spanish flu," Zuckerman wrote.
"We must prioritize research money to develop a vaccine, expand the production of flu vaccine, and stockpile antiviral medications," he advised.
On December 8, 2005, Bloomberg ran an article with the headline, "Bird Flu Pandemic May Cost U.S. Economy $675 Billion," in which Senate Majority Leader Bill Frist was quoted as saying, "A pandemic of bird flu in humans may cost the U.S. economy $675 billion, including lost work time and disruptions in supply chains."
This time around, on October 14, 2009, ABC News reported that "the Trust for America's Health, a Washington-based non-profit organization, estimates that a severe pandemic could push down GDP by more than 5 percent and cost Americans $683 billion."
"We're not seeing a pandemic that's this severe," says Jeff Levi, director of the group. "We've dodged a lot of bullets."
Last but not least, Thomas H Glocer is the Chief Executive Officer of the Thomson Reuters Corporation. On November 26, 2007, Merck announced that Thomas Glocer, Chief Executive Officer, Reuters Group PLC, "will join the Company's Board of Directors effective Nov. 27."
"Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs," the press release stated.
As shown above, the mainstream media cannot be objective when reporting on the swine flu because it is riddled with conflicts of interest involving the vaccine industry.
Part V
Related
- The FDA’s Peramivir H1N1 Swine Flu Experiment
- Ten Swine Flu Lies Told by the Mainstream Media
- Florida Hospital Caught in Swine Flu Cover-Up?
- Ten swine flu lies told by the media
- H1N1: To Jab or Not to Jab?
- Ten Things You're Not Supposed to Know about the Swine Flu Vaccine
- Proof that European H1N1 Vaccines Contain Mercury, Squalene and TWEEN 80
- Flu vaccines revealed as the greatest quackery ever pushed in the history of medicine
Source: http://www.naturalnews.com
Sem comentários:
Enviar um comentário